Clinical trial · Observational
Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Although immunotherapy revolutionized melanoma outcomes over the last 10 years, only 40-50% of patients respond to treatments and 25% develop acquired resistances. Natural Killer (NK) cells naturally recognize and kill tumor cells. However, the immunosuppressive micro-environment generated by the tumor decreases NK cells' killing activity. CD160 is a NK cell receptor identified and characterized in our laboratory. Engagement of the GPI isoform (CD160-GPI) initiates NK cell cytotoxic response. Upon NK cell activation, a transmembrane isoform (CD160-TM) is neo-synthesized which promotes the amplification of activated NK cell cytotoxicity. The aim of this study is to assess the phenotypic profile of advanced stages melanoma patients' NK cells (mainly CD160-TM expression or its induction) and therefore the therapeutic potential of the use of an anti-CD160-TM agonist antibody to boost the NK-dependent mechanism leading to tumor depletion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Percentage of effector cells activation and degranulation (CD69 and CD107a staining )
- timeFrame
- at inclusion
- description
- Difference between cells incubated with the anti CD160-TM antibody and with isotipic control ab ( flow cytometry)
Secondary outcomes (18)
- measure
- Overall survival
- timeFrame
- at 1 year post inclusion
- measure
- Overall survival
- timeFrame
- at 2 years post inclusion
- measure
- Overall survival
- timeFrame
- at 3 years post inclusion
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria : * Patients aged18-years old or over * ECOG score between 0-2 * Inoperable stage III or stage IV melanoma * Naïve of treatment or in progression after one or several treatment lines * Give their written consent for the present study and be included in MelBase cohort. * health insurance coverage. Supplementary inclusion criteria for part II : * skin or subcutaneous melanoma lesions * agree and inform consent for a cutaneous biopsy or a tumor sample if presenting lymph nodes involvement if part of the usual clinical practice. Exclusion Criteria: * Pregnant and breastfeeding women * Patients with psychiatric disorders * Patients already included in another clinical trial * Having received chemotherapy or radiotherapy during the last 4 weeks, * Patient presenting another solid or blood cancer, chronic viral infection (e.g. HIV, HBV or HCV) * Been treated with more than 10mg of steroids until the 4 weeks before inclusion. * Refusal to participate to the study * Patients under guardianship or curatorship * Patients on state medical aid
References
Publications (0)
Data not yet available